Cargando…

Clinical genetics of melanoma

Mostrar otras versiones (1)

Detalles Bibliográficos
Autor principal:	Debniak, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108164/ http://dx.doi.org/10.1186/1897-4287-9-S2-A10

Ejemplares similares

Clinical genetics of melanoma
por: Dębniak, T
Publicado: (2012)

Genome-wide association studies identify new melanoma susceptibility loci
por: Dębniak, Tadeusz
Publicado: (2012)

Fast diagnostic test for the identification of an increased genetic predisposition to colon cancer (exemplified on a DNA test for recurrent mutations of the gene MMR)
por: Kurzawski, G, et al.
Publicado: (2012)

Cumulative small effect genetic markers and the detection of advanced colorectal neoplasias by population screening
por: Kurlapska, A, et al.
Publicado: (2012)

Rapid test for detection of high risk of breast cancer
por: Durda, K, et al.
Publicado: (2012)

Clinical practice improvement in the genetics clinic
por: Greening, S
Publicado: (2012)

Vitamins A, E and D and cancer risk in BRCA1 carriers
por: Kąklewski, K, et al.
Publicado: (2012)

Cancer predisposing BARD1 mutations in breast-ovarian cancer families
por: Ratajska, Magdalena, et al.
Publicado: (2012)

Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin
por: Dębniak, Tadeusz
Publicado: (2007)

US28 in melanoma growth
por: Moser, Elisabeth, et al.
Publicado: (2008)

Targeting oncogenes in advanced melanoma
por: McArthur, GA
Publicado: (2012)

Clinical genetics in cancer prevention
por: Elsakov , Pavel
Publicado: (2012)

Progress in clinical genetics of prostate cancer
por: Cybulski, C, et al.
Publicado: (2011)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

Prognostic value of tumor markers in malignant melanoma
por: Treskova, Inka, et al.
Publicado: (2014)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Iron and breast cancer risk
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

PW02-031 - Genetic and clinical manifestations of CAPS
por: Bybee, AK, et al.
Publicado: (2013)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Melanoma in the elderly patient: a single institution retrospective analysis
por: Desiato, Vincenzo, et al.
Publicado: (2013)

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
por: Hirsh, Vera, et al.
Publicado: (2017)

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
por: Carbone, David, et al.
Publicado: (2018)

Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts
Publicado: (2019)

Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts
Publicado: (2021)

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts
Publicado: (2022)

PW01-034 – Clinical-genetic investigation of FMF in Armenia
por: Hayrapetyan, H, et al.
Publicado: (2013)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Simvastatin targets the IL-6 signalling cascade in human melanoma cells
por: Wasinger, Christine, et al.
Publicado: (2011)

Statins induce apoptosis in human melanoma cells via multiple pathways
por: Minichsdorfer, Christoph, et al.
Publicado: (2008)

Meeting abstracts from the Annual Conference “Clinical Genetics of Cancer 2022”
Publicado: (2023)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

Sentinel node biopsy and radical lymph node dissection for advanced melanoma in the elderly
por: Desiato, V, et al.
Publicado: (2011)

From GWAS to genome sequencing: complementary approaches to identify melanoma predisposition genes
por: MacGregor, S, et al.
Publicado: (2012)

Cytokine signalling in human melanoma cells determines susceptability to statin-induced apoptosis
por: Minichsdorfer, Christoph, et al.
Publicado: (2009)

Melanoma and immunotherapy bridge 2015: Naples, Italy. 1–5 December 2015
por: Nanda, Vashisht G. Y., et al.
Publicado: (2016)

Methotrexate (MTX) inhibition of cytokine production: relationship with clinical outcome and genetic polymorphisms
por: Sabina, P, et al.
Publicado: (2003)

Clinical Genetics of Cancer 2017: Szczecin, Poland. 21-22 September 2017
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2q5adlaus9k51fjivs99je7g2i